Overview

This trial is active, not recruiting.

Conditions fallopian tube cancer, ovarian cancer, primary peritoneal cancer
Treatments amg 386, amg 386 placebo, paclitaxel
Phase phase 3
Target ANG
Sponsor Amgen
Start date November 2010
End date March 2013
Trial size 919 participants
Trial identifier NCT01204749, 20090508

Summary

The purpose of this study is to determine if treatment with paclitaxel plus AMG 386 is superior to paclitaxel plus placebo in women with recurrent partially platinum sensitive or resistant epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer.

AMG 386 is a man-made medication that is designed to stop the development of blood vessels in cancer tissues. Cancer tissues rely on the development of new blood vessels, a process called angiogenesis, to obtain a supply of oxygen and nutrients to grow.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking double blind (subject, caregiver, investigator, outcomes assessor)
Primary purpose treatment
Arm
(Experimental)
Arm A: Paclitaxel 80mg/m2 IV QW and Blinded AMG 386 15mg/kg IV QW
amg 386 Angiogenesis inhibitor
Weekly Intravenous (IV) AMG 386 15 mg/kg
paclitaxel Taxol USPI, 2007; Taxol SPC, 2009
Paclitaxel 80 mg/m2 intravenous (IV) weekly (3 on/1 off)
(Placebo Comparator)
Arm B: Paclitaxel 80mg/m2 IV QW and Blinded AMG 386 Placebo IV QW
amg 386 placebo Placebo comparator
Weekly Intravenous (IV) placebo 15 mg/kg
paclitaxel Taxol USPI, 2007; Taxol SPC, 2009
Paclitaxel 80 mg/m2 intravenous (IV) weekly (3 on/1 off)

Primary Outcomes

Measure
Progression-Free Survival
time frame: 8 Months on average

Secondary Outcomes

Measure
Overall survival
time frame: 20 months on average
Objective Response Rate
time frame: From Baseline (if subject has Measurable Disease) until objective response (radiologic)
Duration of response
time frame: From Baseline until progression
CA-125 response rate per Gynecologic Cancer Intergroup (GCIG) and change in CA-125
time frame: From Baseline until CA-125 response
Incidence of adverse events and significant laboratory abnormalities
time frame: 8 Months on average
Pharmacokinetics of AMG 386 (Cmax and Cmin)
time frame: Week 1 until week 9 of treatment
Incidence of the occurrence of anti-AMG 386 antibody formation
time frame: Week 1 until maximum of 1-year following last dose of study drug
Patient reported Health Related Quality of Life (HRQOL) and ovarian cancer related symptoms using Functional Assessment of Cancer Therapy - Ovary questionnaire (FACT-O)
time frame: From week 1 until 30-days following last study drug administration
Overall health status using EuroQOL(EQ-5D)
time frame: From week 1 until 30-days following last study drug administration

Eligibility Criteria

Female participants at least 18 years old.

Inclusion Criteria: - Female 18 years of age or older at the time the written informed consent is obtained - Gynecologic Oncology Group (GOG) Performance Status of 0 or 1 - Life expectancy >= 3 months (per investigator opinion) - Histologically or cytologically documented invasive epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer (Subjects with pseudomyxoma , mesothelioma, unknown primary tumor, sarcoma, or neuroendocrine histology, with borderline ovarian cancer, ie, subjects with low malignant potential tumors, and with clear cell or mucinous histology are excluded) - Subjects must have undergone surgery for ovarian cancer, primary peritoneal cancer, or fallopian tube cancer including at least a unilateral oophorectomy - Radiologically evaluable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 with modifications - Subjects must have had one prior platinum-based chemotherapeutic regimen for management of primary disease containing carboplatin, cisplatin, or another organoplatinum compound. This initial treatment may have included intraperitoneal therapy, high-dose therapy, consolidation therapy, bevacizumab or extended therapy administered after surgical or non-surgical assessment. - Adequate organ and hematological function - Generally well controlled blood pressure with systolic blood pressure <= 140 mmHg and diastolic blood pressure <= 90 mmHg prior to randomization. The use of anti-hypertensive medications to control hypertension is permitted - Radiographically documented disease progression either on or following the last dose of prior chemotherapy regimen for epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer Exclusion Criteria: - Subjects who have received more than 3 previous regimens of anti-cancer therapy for epithelial ovarian, primary peritoneal or fallopian tube cancers - Subjects who have received paclitaxel as consolidation therapy, maintenance, or monotherapy are excluded - Subjects with primary platinum-refractory disease - Subjects with platinum-free interval (PFI) > 12 months from their last platinum based therapy - Radiotherapy <= 14 days prior to randomization. Subjects must have recovered from all radiotherapy-related toxicities - Previous abdominal or pelvic radiotherapy - History of arterial or venous thromboembolism within 12 months prior to randomization - History of clinically significant bleeding within 6 months prior to randomization - History of central nervous system metastasis - Has not yet completed a 21 day washout period prior to randomization for any previous anti cancer systemic therapies (30 days for prior bevacizumab) - Enrolled in or has not yet completed at least 30 days (prior to randomization) since ending other investigational device or drug, or currently receiving other investigational treatments - Unresolved toxicities from prior systemic therapy that are Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 >= Grade 2 in severity except alopecia - Known active or ongoing infection (except uncomplicated urinary tract infection [UTI]) within 14 days prior to randomization - Currently or previously treated with AMG 386, or other molecules that inhibit the angiopoietins or Tie2 receptor - Treatment within 30 days prior to randomization with strong immune modulators including but not limited to systemic cyclosporine, tacrolimus, sirolimus, mycophenolate mofetil, methotrexate, azathioprine, rapamycin, thalidomide, and lenalidomide - Clinically significant cardiovascular disease within 12 months prior to randomization - Major surgery within 28 days prior to randomization or still recovering from prior surgery - Minor surgical procedures, except placement of tunneled central venous access device within 3 days prior to randomization. Diagnostic laparoscopy is regarded as a minor surgical procedure.

Additional Information

Official title A Phase 3, Randomized, Double-Blind Trial of Weekly Paclitaxel Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers
Trial information was received from ClinicalTrials.gov and was last updated in August 2016.
Information provided to ClinicalTrials.gov by Amgen.